{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:56:15Z","timestamp":1773370575920,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1245\/s10434-025-18977-0","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:51:09Z","timestamp":1767433869000},"page":"3501-3511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platinum-Based Chemotherapy Versus Secondary Cytoreductive Surgery Before Olaparib Maintenance Therapy for 259 Patients with BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer: A Multicenter Retrospective Study:\u00a0Comparative Effectiveness and Survival Outcomes Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Dong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenpei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"18977_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin."},{"key":"18977_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156:1336\u201346.","journal-title":"Int J Cancer."},{"key":"18977_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol."},{"key":"18977_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.hoc.2018.07.005","volume":"32","author":"S Armbruster","year":"2018","unstructured":"Armbruster S, Coleman RL, Rauh-Hain JA. Management and treatment of recurrent epithelial ovarian cancer. Hematol Oncol Clin N. 2018;32:965\u201382.","journal-title":"Hematol Oncol Clin N."},{"key":"18977_CR5","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1200\/JCO.21.02085","volume":"40","author":"MH Baek","year":"2022","unstructured":"Baek MH, Park EY, Ha HI, et al. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis. J Clin Oncol. 2022;40:1659\u201370.","journal-title":"J Clin Oncol."},{"key":"18977_CR6","doi-asserted-by":"crossref","unstructured":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer. New Engl J Med. 2022;386:704.","DOI":"10.1056\/NEJMx220002"},{"key":"18977_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439\u201349.","journal-title":"Lancet Oncol."},{"key":"18977_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391.","journal-title":"Lancet Oncol."},{"key":"18977_CR9","doi-asserted-by":"publisher","first-page":"1512339","DOI":"10.3389\/fonc.2024.1512339","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yang Y, Guo B, et al. Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer. Front Oncol. 2024;14:1512339.","journal-title":"Front Oncol."},{"key":"18977_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/GCO.0000000000000931","volume":"36","author":"V Salutari","year":"2024","unstructured":"Salutari V, Giudice E, Lorusso D. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives. Curr Opin Obstet Gyn. 2024;36:9\u201317.","journal-title":"Curr Opin Obstet Gyn."},{"key":"18977_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/GRF.0000000000000500","volume":"63","author":"C Gnade","year":"2020","unstructured":"Gnade C, McDonald ME. Maintenance therapy in the treatment of recurrent epithelial ovarian cancer. Clin Obstet Gynecol. 2020;63:86\u201391.","journal-title":"Clin Obstet Gynecol."},{"key":"18977_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.771836","volume":"12","author":"L Gao","year":"2021","unstructured":"Gao L, Chen R, Li T, Li L, Zheng Q. Quantitative analysis of the efficacy of PARP inhibitors as maintenance therapy in recurrent ovarian cancer. Front Pharmacol. 2021;12:771836.","journal-title":"Front Pharmacol."},{"key":"18977_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:620\u201331.","journal-title":"Lancet Oncol."},{"key":"18977_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ygyno.2021.12.025","volume":"164","author":"A Poveda","year":"2022","unstructured":"Poveda A, Lheureux S, Colombo N, et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1\/BRCA2 mutation: OPINION primary analysis. Gynecol Oncol. 2022;164:498\u2013504.","journal-title":"Gynecol Oncol."},{"key":"18977_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021;32:512\u201321.","journal-title":"Ann Oncol."},{"key":"18977_CR16","doi-asserted-by":"crossref","unstructured":"Wu X, Zhu J, Yin R, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. EClinicalMedicine. 2024;72:102629","DOI":"10.1016\/j.eclinm.2024.102629"},{"key":"18977_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2025.04.580","volume":"197","author":"A Poveda","year":"2025","unstructured":"Poveda A, Lheureux S, Colombo N, et al. Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and\/or BRCA2 mutation: final overall survival results from the OPINION trial. Gynecol Oncol. 2025;197:74\u201382.","journal-title":"Gynecol Oncol."},{"key":"18977_CR18","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Benigno B, Dorum A, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial. Gynecol Oncol. 2020;159:442\u20138.","journal-title":"Gynecol Oncol."},{"key":"18977_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","volume":"195","author":"UA Matulonis","year":"2025","unstructured":"Matulonis UA, Herrstedt J, Oza A, et al. ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety. Gynecol Oncol. 2025;195:192\u20139.","journal-title":"Gynecol Oncol"},{"key":"18977_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet."},{"key":"18977_CR21","first-page":"332","volume":"18","author":"D Margul","year":"2020","unstructured":"Margul D, Coleman RL, Herzog TJ. The current status of secondary cytoreduction in ovarian cancer: a systematic review. Clin Adv Hematol Oncol. 2020;18:332\u201343.","journal-title":"Clin Adv Hematol Oncol."},{"key":"18977_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II, a project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289\u201395.","journal-title":"Int J Gynecol Cancer."},{"key":"18977_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.11.009","volume":"6","author":"AA Butala","year":"2021","unstructured":"Butala AA, Patel RR, Manjunath S, et al. Palliative radiation therapy for metastatic, persistent, or recurrent epithelial ovarian cancer: efficacy in the era of modern technology and targeted agents. Adv Radiat Oncol. 2021;6:100624.","journal-title":"Adv Radiat Oncol."},{"key":"18977_CR24","doi-asserted-by":"crossref","unstructured":"Onoprienko A, Bartl T, Grimm C, Concin N, Polterauer S. Novel targeted agents in advanced and recurrent low-grade serous ovarian cancer: a silver lining in the therapy of a chemoresistant disease? Cancers (Basel). 2024;16(19):3268.","DOI":"10.3390\/cancers16193268"},{"key":"18977_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026849","volume":"100","author":"L Liu","year":"2021","unstructured":"Liu L, Xiong W. Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer: a systematic review and meta-analysis. Medicine. 2021;100:e26849.","journal-title":"Medicine."},{"key":"18977_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2019.08.006","volume":"155","author":"YL Liu","year":"2019","unstructured":"Liu YL, Zhou Q, Iasonos A, et al. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecol Oncol. 2019;155:51\u20137.","journal-title":"Gynecol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18977-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18977-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18977-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:38Z","timestamp":1773330458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18977-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18977"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18977-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}